Page last updated: 2024-09-23

glycyl-glycyl-glycyl-glycine

Cross-References

ID SourceID
PubMed CID69481
CHEMBL ID378905
SCHEMBL ID93766
MeSH IDM0134153

Synonyms (40)

Synonym
nsc-89178
637-84-3
nsc89178
glycine, n-[n-(n-glycylglycyl)glycyl]-
glycylglycylglycylglycine
glycyl-glycyl-glycyl-glycine
gly-gly-gly-gly
NCIOPEN2_005522
tetraglycine
2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetic acid
CHEMBL378905
h-gly-gly-gly-gly-oh
G0127
AKOS009159037
unii-t171gru26b
t171gru26b ,
n-(n-(n-glycylglycyl)glycyl)glycine
nsc 89178
einecs 211-303-4
FT-0632710
SCHEMBL93766
([(([(aminoacetyl)amino]acetyl)amino)acetyl]amino)acetic acid #
DTXSID50213103
glycine, n-(n-(n-glycylglycyl)glycyl)-
(triglycyl)glycine
glycine tetrapeptide
glycine, glycylglycylglycyl-
gly4
mfcd00008129
glycyl-glycyl-glycyl-glycine (h-gly-gly-gly-gly-oh)
CS-0204513
2-(2-(2-(2-aminoacetamido)acetamido)acetamido)acetic acid
Q27289539
A852237
T72755
tetraglycine; glycylglycylglycylglycine; glycyl-glycyl-glycyl-glycine; gly-gly-gly-gly
2-(2-(2-(2-aminoacetamido)acetamido)acetamido)aceticacid
BS-23865
HY-W142467
2-{2-[2-(2-aminoacetamido)acetamido]acetamido}acetic acid

Bioassays (10)

Assay IDTitleYearJournalArticle
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID266247Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266249Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID388081Antifungal activity at Candida albicans2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID388086Antibacterial activity at Escherichia coli2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID680762TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.004 uM, Gly4: 5000 uM) in Xenopus laevis oocytes2003The Journal of pharmacy and pharmacology, Jul, Volume: 55, Issue:7
Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin.
AID682118TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.004 uM, Gly5: 5000 uM) in Xenopus laevis oocytes2003The Journal of pharmacy and pharmacology, Jul, Volume: 55, Issue:7
Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin.
AID388088Antifungal activity at Candida albicans assessed as concentration required to lower the MIC of fluconazole from 32 to 1 ug/mL after 48 hrs2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
AID266246Activation of human PEPT1 expressed in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID388089Antibacterial activity at Escherichia coli assessed as concentration required to lower the MIC of erythromycin from 64 to 1 ug/mL after 24 hrs2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (10.34)18.7374
1990's2 (6.90)18.2507
2000's12 (41.38)29.6817
2010's10 (34.48)24.3611
2020's2 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Safety/Toxicity (1)

ArticleYear
Biodegradable Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Safe Adjuvant for Mucosal Vaccination.
Molecular pharmaceutics, 03-04, Volume: 16, Issue: 3
2019
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (1)

ArticleYear
Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 154
2020
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]